Google Scholar: citations
Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior
Revilla, Giovanna (Institut d'Investigació Biomèdica Sant Pau)
Al Qtaish, Nuseibah (Amman Arab University)
Caruana Santiago, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Sainz-Ramos, Myriam (Universidad del País Vasco)
Lopez-Mendez, Tania (Universidad del País Vasco)
Rodríguez, Francisco (Institut d'Investigació Biomèdica Sant Pau)
Paez-Espinosa, Verónica (Pontificia Universidad Católica del Ecuador)
Li, Changda (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Vallverdú, Núria Fucui (Institut d'Investigació Biomèdica Sant Pau)
Edwards, Maria (Institut d'Investigació Biomèdica Sant Pau)
Moral, Antonio (Institut d'Investigació Biomèdica Sant Pau)
Pérez, José Ignacio (Institut d'Investigació Biomèdica Sant Pau)
Escolà-Gil, Joan Carles (Institut d'Investigació Biomèdica Sant Pau)
Pedraz, José Luis (NanoBioCel Research Group)
Gallego, Idoia (NanoBioCel Research Group)
Corcoy i Pla, Rosa (Institut d'Investigació Biomèdica Sant Pau)
Céspedes, María Virtudes (Institut d'Investigació Biomèdica Sant Pau)
Puras, Gustavo (NanoBioCel Research Group)
Mato, Eugènia (Institut d'Investigació Biomèdica Sant Pau)

Date: 2023
Abstract: Background: Lenvatinib, a tyrosine kinase inhibitor (TKI) approved for the treatment of progressive and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), is associated with significant adverse effects that can be partially mitigated through the development of novel drug formulations. The utilization of nanoparticles presents a viable option, as it allows for targeted drug delivery, reducing certain side effects and enhancing the overall quality of life for patients. This study aimed to produce and assess, both in vitro and in vivo, the cytotoxicity, biodistribution, and therapeutic efficacy of lenvatinib-loaded PLGA nanoparticles (NPs), both with and without decoration using antibody conjugation (cetuximab), as a novel therapeutic approach for managing aggressive thyroid tumors. Methods: Poly(lactic-co-glycolic acid) nanoparticles (NPs), decorated with or without anti-EGFR, were employed as a lenvatinib delivery system. These NPs were characterized for size distribution, surface morphology, surface charge, and drug encapsulation efficiency. Cytotoxicity was evaluated through MTT assays using two cellular models, one representing normal thyroid cells (Nthy-ori 3-1) and the other representing anaplastic thyroid cells (CAL-62). Additionally, an in vivo xenograft mouse model was established to investigate biodistribution and therapeutic efficacy following intragastric administration. Results: The NPs demonstrated success in terms of particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and cetuximab distribution across the surface. In vitro analysis revealed cytotoxicity in both cellular models with both formulations, but only the decorated NPs achieved an ID50 value in CAL-62 cells. Biodistribution analysis following intragastric administration in xenografted thyroid mice demonstrated good stability in terms of intestinal barrier function and tumor accumulation. Both formulations were generally well tolerated without inducing pathological effects in the examined organs. Importantly, both formulations increased tumor necrosis; however, decorated NPs exhibited enhanced parameters related to apoptotic/karyolytic forms, mitotic index, and vascularization compared with NPs without decoration. Conclusions: These proof-of-concept findings suggest a promising strategy for administering TKIs in a more targeted and effective manner.
Grants: Instituto de Salud Carlos III PI19/00136
Instituto de Salud Carlos III PI20/00770
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès
Document: Article ; recerca ; Versió publicada
Subject: Thyroid ; Nanoparticles ; EGFR ; Lenvatinib
Published in: Biomolecules, Vol. 13 (november 2023) , ISSN 2218-273X

DOI: 10.3390/biom13111647
PMID: 38002329


19 p, 4.6 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles

 Record created 2024-04-24, last modified 2026-03-12



   Favorit i Compartir